Biopharma stocks tumble as drug supply chain risk mounts

Biotech indexes lost considerable ground during Monday’s trading session amid concerns of global supply chain disruptions due to the COVID-19 outbreak, although biotechs were generally spared the worst of the day’s losses, dipping by a slimmer percentage than indexes that measured the broader markets.

FDA and U.S. trade associations continue to express confidence in the U.S. supply chain, while the European generic trade association is asking regulators to step in to prevent shortages...